For seminal translational discoveries in breast cancer research that have led to significant improvements in diagnosis and treatment. This team has led the discovery of new therapeutic approaches and the biomarkers that identify the populations of patients that gain most benefit from them. Examples being PARP inhibitors, that have changed how patients and breast cancers with BRCA1/2 mutations are tested and treated, as well as development of aromatase inhibitors in estrogen receptor positive breast cancer and predictive biomarkers that have informed how systemic treatments may be selected, deescalated or adapted following evidence of therapeutic response or resistance. This effective team has also lead work that has fundamentally changed international radiotherapy dose fractionation to reduce treatment duration and characterized molecular changes occurring in breast cancer that contribute to metastatic colonization, resistance to cell death and vulnerability to targeted therapies